Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
A phase 2 trial of Parsaclisib, Ruxolitinib and Ibrutinib in advanced solid tumours, run by Incyte Corporation, active and no longer recruiting.
Overview
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) is a phase 2 interventional study registered as NCT04509700 by Incyte Corporation, with 112 participants enrolled, started 2020-08-03 and due to reach its primary completion in 2026-11-05. Interventions recorded: Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib and parsaclisib + ibrutinib.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Shares Incyte, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialExtension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Shares Incyte, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTrial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Shares Ibrutinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TreatmentINCA33890
Shares Incyte and the tag pipeline.
- TrialStudy of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Shares Ibrutinib and the tag pipeline.
- TrialA Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Shares Ruxolitinib and the tag pipeline.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Ibrutinib and the tag pipeline.
- TrialStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Shares Ibrutinib and the tag pipeline.